Treatment of human prostate cancer cells, which highly express Hsp27, with atractylenolide I has been reported to suppress Hsp27 expression, thereby reducing cell viability and inducing apoptosis [20]. The gene discussed is HSPB1; the disease is Familial prostate cancer.